Current known active infection with HIV, hepatitis B virus, or hepatitis C virus
Known human immunodeficiency virus (HIV) or known active hepatitis B virus or hepatitis C virus infection
Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.
No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status.
Subjects with known active human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection
Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
Known active hepatitis A, B, or C virus infection
Known infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti hepatitis C virus positive)
Subjects with a known history of human immunodeficiency virus  and , human T lymphotropic virus , hepatitis B virus, or active hepatitis C virus.
Positive human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection.
Known infection of, or who test positive for, human immunodeficiency virus, hepatitis B virus or hepatitis C virus.
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Active HIV, hepatitis C virus, or hepatitis B virus infection(s)
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus (testing not required prior to enrollment)\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters
Known active hepatitis A, B or C virus infection
Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection
Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus
Has evidence of active hepatitis B virus or hepatitis C virus
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.
Known history of human immunodeficiency virus infection or an active hepatitis B or C virus infection (exception: this criteria does not apply to patients with cervical/anal tumours enrolling in Cohort )
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Known hepatitis B virus, hepatitis C virus or HIV infection
Patients with a known active infection, e.g., hepatitis B virus or hepatitis C virus; human immunodeficiency virus (HIV)-positive patients who are otherwise well and who do not have evidence of significant immune compromise are eligible
Has known active infection with hepatitis B virus or hepatitis C virus
Must not have evidence of previous or current infection with hepatitis B virus
Known active hepatitis C virus, or known active hepatitis B virus
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known hepatitis B virus, hepatitis C virus or HIV infection
Positivity for human immunodeficiency virus (HIV)-/HIV-, Hepatitis B virus, and Hepatitis C virus active infection
Known active infection with HIV, hepatitis B virus, or hepatitis C virus
Positivity for human immunodeficiency virus (HIV)-/HIV-, hepatitis B virus, and hepatitis C virus active infection
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence\r\nof cirrhosis AND the patients liver function tests fall within the parameters set
Known hepatitis B virus, hepatitis C virus or HIV infection
Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus; patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters set above
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness will be excluded from the study; HIV-positive patients on combination antiretroviral therapy are ineligible
Patients with active severe infection; known infection with human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, or severe concurrent illness
Active infection with hepatitis A, B or C virus
Known active hepatitis C virus, or known active hepatitis B virus
Patients with known human immunodeficiency virus (HIV) or active infection with hepatitis C virus or hepatitis B virus (testing is not mandatory)
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Known active infection with HIV or Hepatitis B or C virus
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Have active or uncontrolled clinically serious hepatitis B virus or hepatitis C virus infection.
Known infection with HIV or chronic infection with hepatitis B virus or hepatitis C virus
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known history of human immunodeficiency virus (HIV), active hepatitis C virus, active hepatitis B\r\nvirus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Known active hepatitis C virus, or known active hepatitis B virus
Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection (including undetectable viral loads while on antiviral therapy) and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Patients with known active hepatitis B virus or hepatitis C virus acute or chronic infection
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection, or any uncontrolled active systemic infection \r\n* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated
Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known active or chronic infection with human immunodeficiency virus.
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Known hepatitis B virus, hepatitis C virus or HIV infection
Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Patients with active liver disease, for example, due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis
Documentation of hepatitis B virus and hepatitis C virus serology is required
Clinical evidence of active infection of any type, including hepatitis B or C virus
Known hepatitis B virus, hepatitis C virus or HIV infection;
Ongoing or active systemic infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus hepatitis, or known active hepatitis C virus hepatitis
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters set in inclusion criteria number c, hepatic function
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection
Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
Active severe infection, or known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus\r\n* Patients with chronic hepatitis C virus may be enrolled if there is no clinical/laboratory evidence of cirrhosis AND the patients liver function tests fall within the parameters set
Active infection with Hepatitis B virus or Hepatitis C virus
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known history of human immunodeficiency virus or active infection with hepatitis C virus or hepatitis B virus or any uncontrolled active systemic infection
Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.
Infection with Human immunodeficiency virus (HIV) or hepatitis B virus, hepatitis C\n             virus
Active hepatitis B and C virus infection
Known active infection with hepatitis A, B or C virus
Known history of infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)
A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection.
Known intercurrent infections (including hepatitis C virus and human immunodeficiency virus or other conditions), or clinical evidence of these conditions
Hepatitis B Virus, or Hepatitis C Virus infection (subjects with laboratory evidence of Hepatitis B Virus clearance may be enrolled).
Known active infection with HIV, Hepatitis B or C virus
Known active hepatitis B virus infection
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.
Currently known active infection with HIV, hepatitis B or C virus
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Known history of human immunodeficiency virus (HIV) or active hepatitis C Virus or active hepatitis B virus infection or any uncontrolled active systemic infection
Active hepatitis C virus
Active hepatitis B or C virus
Human Immunodeficiency Virus, Hepatitis B Virus or Hepatitis C Virus infection.
Active infection with Hepatitis B virus or Hepatitis C virus
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, entecavir), ribavirin, or interferon alpha within  weeks of initiation of study treatment.
Has acute or chronic active hepatitis B virus or hepatitis C virus infection or received treatment with nucleotide analogs such as those used in the treatment of hepatitis B virus (eg, lamivudine, adefovir, tenofovir, telbivudine, and entecavir), ribavirin, or interferon alpha within  weeks of initiation of study treatment.